I N T RO D U C T I O N
Decreased estimated glomerular filtration rate (eGFR) is a wellknown risk factor for high all-cause death, cardiovascular events and cardiovascular death [1] [2] [3] . Vascular calcification is an important explanation for the adverse outcomes observed in chronic kidney disease (CKD).
The level of coronary artery calcification (CAC) measured by computed tomography (CT) is useful for non-invasively and quantitatively predicting cardiovascular outcome [4] . CAC is typically increased in dialysis patients [5] and is also associated with lower eGFR in CKD patients not on dialysis [6] . Furthermore, CAC is a strong predictor of mortality and cardiovascular events in patients with CKD [7] .
Importantly, both high and low eGFR are associated with adverse outcomes, although the underlying mechanism is not clear [8] . Previous studies have shown that eGFR has a u-shape relationship with cardiovascular outcome and all-cause mortality [3, 9] . Most studies on the relationship between eGFR and vascular calcification have focused on decreased eGFR, and there are little data in subjects without CKD. Verification of the association between high eGFR and vascular calcification will be helpful in understanding the mechanism underlying worse cardiovascular outcome in subjects with high eGFR. The aim of this study is to investigate the relationship between high eGFR and CAC by analyzing coronary artery calcium scores (CACS) form middle-aged Korean men who participated in a health check-up program.
M AT E R I A L S A N D M E T H O D S
Study design and population This is a cross-sectional study designed to examine the association between high eGFR and CAC in relatively healthy middle-aged Korean men without chronic kidney disease.
Study subjects were participants at health maintenance exams at the Kangbuk Samsung Hospital, Sungkyunkwan University, Seoul, Korea. A total of 9194 middle-aged men between 45 and 60 years old underwent coronary computed tomographic scan from 2010 to 2012, and they were considered for inclusion in this study. There were 1702 records with missing data regarding the variables of interest, which were excluded. A total of 506 participants with underlying CKD, history of cardiovascular disease (CVD) and history of cancer were excluded (CKD, n = 180; history of CVD, n = 175; history of cancer, n = 171). CKD was defined as an eGFR under 60 mL/min/1.73 m 2 or as dipstick proteinuria ≥1+ at baseline exam. The final analysis included 6986 participants. Figure 1 summarizes the process of recruiting this study population. This study was approved by the institutional review board at Kangbuk Samsung Hospital.
Clinical and laboratory measurements
Data regarding medical history, medication usage and healthrelated behaviors were collected through a self-administered questionnaire. Trained staff collected anthropometry, blood pressure and serum biochemical measures. A more detailed protocol of this examination program has been previously described [10] . In addition, trained nurses measured height and weight with an automated scale while the participants were wearing a light hospital gown and no shoes. Body mass index (BMI) was calculated as weight in kilograms divided by height in meters squared.
Blood samples were taken from an antecubital vein after fasting for at least 10 h. Serum total cholesterol, triglycerides and uric acid levels were determined using an enzymatic colorimetric assay. Low-density lipoprotein (LDL) cholesterol and highdensity lipoprotein (HDL) cholesterol were measured directly using a homogeneous enzymatic colorimetric assay. Serum high-sensitivity C-reactive protein (hsCRP) was determined using a particle-enhanced immunoturbidimetric assay on a Modular Analytics P800 apparatus (Roche Diagnostics). Serum insulin was measured using an electrochemiluminescence immunoassay on a Modular Analytics E170 apparatus (Roche Diagnostics). Serum glucose was measured using the hexokinase method on a Cobas Integra 800 apparatus (Roche Diagnostics; Rotkreuz, Switzerland). Insulin resistance was assessed with a homeostatic model assessment of insulin resistance (HOMA-IR) according to the following equation: fasting blood insulin (uU/mL) × fasting serum glucose (mg/dL)/405. Serum creatinine levels were measured by the isotope dilution mass spectroscopy-traceable method using Modular D2400 (Roche, Tokyo, Japan). eGFR was calculated using the CKD epidemiology collaboration (CKD-EPI) equation [11] as follows: eGFR = 141 × min (serum creatinine/κ,1) α × max (serum creatinine/κ,1) CT scans were performed with a Lightspeed VCT XTe-64 slice MDCT scanner (GE Healthcare, Tokyo, Japan) using a standard scanning protocol described as follows: 2.5 mm thickness, 400 ms rotation time, 120 kV tube voltage and a 124 mAS (310 mA × 0.4 s) tube current under electrocardiography-gated dose modulation. The quantitative CACS were calculated according to a method described by Agatston et al. [4] . In the present study, presence of CAC was defined as a CACS >100.
Hypertension was defined as a systolic blood pressure >140 mmHg or diastolic blood pressure >90 mmHg, or by a history of hypertension or medication for hypertension. Diabetes mellitus was defined by a fasting serum glucose >126 mg/dL, by a history of diabetes or by the use of medication for diabetes. CVD was defined by a history of heart disease, coronary disease or stroke.
Statistical analysis
Participants were divided into four groups according to their eGFR level (60∼74, 75∼89, 90∼104 and 105∼maximum mL/ min/1.73 m 2 ). Continuous variables were expressed as the mean ± standard deviation or median (interquartile range). Continuous variables were compared between two groups using a t-test or the Mann-Whitney U-test, and continuous variables were compared between four groups using analysis of variance or the Kruskal-Wallis test. Categorical variables were expressed as percentages and compared between groups using the χ 2 test. Logistic regression analysis was used to determine the odds ratio (OR) and confidence interval (CI) for the presence of CAC associated with different eGFR levels compared with the reference range group. Subgroup analyses were performed for participants without risk factors such as hypertension, diabetes mellitus and abnormal BMI. Statistical 
O R I G I N A L A R T I C L E
H i g h e G F R a n d c o r o n a r y c a l c i fi c a t i o n analyses were performed using Stata Version 13 (StataCorp LP, College Station, TX, USA).
R E S U LT S
The baseline characteristics of study participants according to eGFR category are summarized in Table 1 . All variables except systolic BP, diastolic BP, HDL cholesterol and phosphorus showed differences across eGFR ranges (P < 0.05). Overall, 321 (4.6%) participants had CAC and 6665 (95.4%) participants had no CAC. Among those with CAC, 252 (3.6%) participants had CACS of 100∼399, 48 (0.7%) participants had CACS of 400∼799 and only 21 (0.3%) participants had CACS more than 800. The percent with CAC was lowest with eGFR of 75∼89 and highest with eGFR of 105∼maximum. The difference between the two groups was statistically significant in χ 2 test with Bonferroni adjustment (3.8% versus 6.6%, P = 0.002).
The characteristics of participants with CAC were compared with those without CAC, as given in Table 2 . As expected, participants with CAC had metabolically worse profiles. They had higher age, BMI, systolic BP, diastolic BP, serum glucose and HOMA-IR along with lower HDL cholesterol. Diabetes and hypertension were more common in participants with CAC. However, more participants with CAC performed vigorous exercise more than once a week. Table 3 summarizes the results of multivariate logistic regression analysis and shows the association between eGFR and CAC. After adjustment for cardiovascular risk factors, the association between high eGFR and CAC remained significant. For example, CAC was associated with eGFR of 105∼maximum in a fully adjusted model 3 (compared with category 75∼89: OR, 2.52; P < 0.001). This model was adjusted for age, BMI, diabetes, hypertension, systolic BP, glucose, LDL cholesterol, HDL cholesterol, triglyceride, hsCRP, calcium, phosphorus, current smoking, alcohol intake and vigorous exercise frequency.
Sensitivity analyses were used to investigate the effects of different CAC cut-offs. There were 1995 individuals (28.6%) with a CACS >0, 812 individuals (11.6%) with a CACS >30 and 594 individuals (8.5%) with a CACS >50. The regression modeling given in Table 3 was repeated with the same explanatory variables of model 3, but the CAC definition was replaced with different cut-offs. Higher eGFR category was significantly associated with CAC in analysis of all three cut-offs (Table 4) .
Multivariate logistic analysis was also performed in participants without major risk factors for CAC. eGFR of 105∼maximum was compared with eGFR of 75∼89 and found to be associated with CAC in participants who do not have hypertension (OR, 2.87; P < 0.001), participants who do not have diabetes (OR, 2.77; P < 0.001) and participants who have normal (18.5∼22.9 kg/m 2 ) BMI (OR, 3.34; P = 0.015) ( Table 5 ) according to Asian BMI classification by World Health Organization [12] .
D I S C U S S I O N
This study found that high eGFR is associated with CAC in middle-aged Korean men who participated in a health check-up program. This relationship was valid even after adjustment for various factors associated with CVD and in subgroups without major risk factors such as hypertension, diabetes and obesity. A number of previous studies have investigated the effect of eGFR on health outcome, but most of them concentrated on low eGFR, which is related to CKD. However, several studies have shown that high eGFR is also associated with worse outcomes.
The largest studies showed an association between high eGFR and increased mortality. A landmark meta-analysis of 21 studies revealed a u-shaped association between eGFR and mortality from all causes and for cardiovascular reasons [3] . Another recent analysis of 1,526,437 Canadians also showed high all-cause mortality in subjects with high eGFR. In this study, a high risk of stroke was observed when patients had high eGFR and heavy proteinuria [9] .
Smaller studies have also been conducted in different populations. Low (<45 mL/min/1.73 m 2 ) or high eGFR (≥120 mL/ min/1.73 m 2 ) was associated with high all-cause mortality in 6261 patients with diabetes followed after stroke [13] . In a study of 958 young Finnish patients, eGFR >120 mL/min/ 1.73 m 2 was associated with high all-cause mortality after ischemic stroke [14] . In the HYVET (HYpertension in the Very Elderly Trial) study, 3845 elderly patients older than 80 were observed for a mean of 2.1 years and cardiovascular events were more common in participants with eGFR ≥75 mL/min/ 1.73 m 2 . Cardiovascular events included fatal and non-fatal stroke, heart failure and myocardial infarction [15] . However, studies that directly analyze the relationship between high eGFR and cardiovascular risk factors are very rare. In a study Adjusted for age, sex, BMI, diabetes, hypertension, systolic BP, glucose, LDL cholesterol, HDL cholesterol, triglyceride, hsCRP, calcium, phosphorus, current smoking, alcohol intake and vigorous exercise frequency. eGFR, estimated glomerular filtration rate; CACs, coronary artery calcium score; CACS, coronary calcium score; CI, confidence interval; BMI, body mass index; BP, blood pressure; LDL, low-density lipoprotein, HDL, high-density lipoprotein; hsCRP, high-sensitivity C-reactive protein.
of 902 relatively obese Italian children, mild-low eGFR (<20th percentile) and high eGFR (>80th percentile) were associated with cardiometabolic factors such as high blood pressure, left ventricular hypertrophy and microalbuminuria [16] . It is unclear why high eGFR is associated with CAC, although a few explanations are suggested. First, high eGFR might not only indicate truly high GFR, but may also be a manifestation of decreased muscle mass. Decreased muscle mass might lower the serum creatinine level to cause higher eGFR. Previous studies have shown the effect of low muscle mass on cardiovascular risk. In cross-sectional studies, sarcopenia was associated with increased arterial stiffness in Japanese women [17] and with the presence of CVD in elderly Koreans [18] . In longitudinal studies, low urinary creatinine excretion reflecting low muscle mass predicted all-cause mortality among healthy men in the USA [19] while it predicted cardiovascular events and all-cause mortality among a general population of the Netherlands [20] .
Secondly, eGFR does not perfectly represent true GFR. For example, the Modification of Diet in Renal Disease (MDRD) and CKD-EPI equations underestimate measured GFR at higher ranges [21] . Although the CKD-EPI equation has greater precision than the MDRD equation, the CKD-EPI equation was developed using mostly whites and blacks [11] and has not been validated in Koreans. Therefore, it is possible that a bias in the eGFR equation might have distorted the true relationship between renal function and CAC.
Finally, it is possible that glomerular hyperfiltration expressed as high eGFR might be a true cardiovascular risk factor involved in the pathogenesis of CAC. Glomerular hyperfiltration is observed in the course of early diabetes [22] and is considered a risk factor for diabetic nephropathy [23] . Glomerular filtration measured by creatinine clearance correlated with left ventricular mass, a marker of target organ damage, in 111 patients with essential hypertension [24] . Another recently published study analyzed the association between GFR measured by iohexol clearance and subclinical CVD in 1521 relatively healthy Norwegians. In this study, high GFR was associated with total carotid plaque area and left ventricular hypertrophy [25] .
Despite the uncertainty regarding a causal relationship, this study is the first to show an association between high eGFR and CAC. The results of this study suggest that close attention should be paid to patients with very high eGFR as well as those with low eGFR to reduce cardiovascular morbidity and mortality. In addition, more studies are needed with a longitudinal design to verify the mechanism underlying this association.
This study has limitations. First of all, because this is a cross-sectional study, a causal relationship between high eGFR and CAC has not been verified. Secondly, the study subjects were all male, Korean and from a single center. Furthermore, they voluntarily participated in a health check-up program or chose to follow the Industrial Safety and Health Law. This study group might not represent the general population and we should be cautious in generalizing the results. Thirdly, low serum creatinine and high eGFR might be caused by decreased muscle mass as mentioned above. Findings would have been more meaningful if we had measured cystatin C and reported CKD-EPI creat-cys. Finally, it is possible that the dipstick test used to exclude the presence of proteinuria was not sensitive enough to identify low level pathological albuminuria.
This study also has strengths. A large sample size is the most important strength of this study. In addition, the association between high eGFR and CAC with different CAC cut-offs was verified. Although many studies using CACS to assess subclinical CVD used an Agatston score of 0 to define CAC, we used a cut-off of 100 for the main analysis. This higher cut-off has significant clinical implications. For example, a CAC cut-off of 100 had sensitivity of 89% and specificity of 77% in detecting cardiovascular events when 1173 asymptomatic patients were followed for an average of 19 months [26] .
In conclusion, compared with eGFR of 75∼89 mL/min/1.73 m 2 , eGFR >105 mL/min/1.73 m 2 was associated with CAC after adjusting for various risk factors associated with CVD in relatively healthy middle-aged Korean men. Careful attention should be paid to patients with higher eGFR in terms of their cardiovascular risks, and further studies are warranted to verify the mechanism linking renal function and vascular calcification.
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